Research Studies

Molnupiravir & Nirmatrelvir/Ritonavir in the Treatment of Systemic Autoimmune Rheumatic Diseases

July 7, 2023

Molnupiravir (MP) and Nirmatrelvir/ritonavir (NM/R) were the first two orally administered antiviral drugs authorized to treat COVID-19. However, the last two phases of clinical trials testing MP and NM/R in COVID-19 were conducted in unvaccinated individuals and before the emergence of the Omicron variant. Additionally, clinical trials didn’t include people suffering from systemic autoimmune rheumatic diseases (SARDs).

Read More »

Caring for Autoimmunity & Long COVID with a Personalized Approach

July 5, 2023

The company Mymee recently published a study on their personalized digital care program for patients living with autoimmune diseases as well as long Covid. Researchers found that over 85% of patients with moderate to severe symptoms saw improvements with their anxiety, depression, fatigue, pain interference, sleep disturbance, and pain intensity while increasing cognitive and physical function.

Read More »

COVID-19 Does Not Increase Risk of Celiac Disease

June 30, 2023

Researchers in Sweden used 1.4 million health records to examine the rate of new Celiac disease diagnoses in those who had experienced a COVID-19 infection versus those who had not. Findings suggested that respiratory diseases do not increase the risk of developing Celiac disease the way gastrointestinal infections do.

Read More »

T-cell Responses in Long Covid Patients

June 28, 2023

In a research letter on long Covid and pulmonary sequelae of COVID-19, authors shared findings around the possibility of viral reservoirs causing prolonged T-cell response in COVID-19 affected patients. The main finding indicated that prolonged infection led to T-cell exhaustion, especially in patients with abnormal lung function and/or structure following a COVID-19 infection.

Read More »
1 2 3 4 5 … 38

Browse By Topic